PIK3CA and head and neck squamous cell carcinoma: It was shown in correlative studies from the E2303 trial of cetuximab-based induction and chemo-radiotherapy in locally advanced HNSCC that PI3K/AKT pathway activation is associated with inferior PFS and OS and may predict resistance to EGFR-targeted therapy [36].